With both sides still out for blood in the battle over their respective anti-anemia erythropoietin products, Transkaryotic Therapies Inc. (which won European approval in March for Dynepo) and Amgen Inc. (guarding the franchise it has, through the blockbuster Epogen) matched lawyers two weeks ago in an appeals hearing that offered few revelations. (BioWorld Financial Watch) Read More